As ER pointed out, the Nov 3rd PR said "We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval." Unless I'm missing something, I interpret that to mean much more than transferring a contract. Also, I believe "at scale" also implies they can produce larger quantites than AGC. And Tuesday's PR said "The Company currently holds sufficient leronlimab to conduct its prospective clinical trial(s) in the short term". I could be wrong but they could be using their current supply as a bridge while they go through the lengthy certification process with the new manufacturer.

Quote:

---

but the thing transferred could be a master or primary contract to produce LL, releasing Samsung from same, instead of the transferring of intellectual property to make manufacturing possible.

---

Quote:

---

Could be a huge new partner… but manufacturing protocols would take time.

---